Stephen Basil Thomas - 07 Aug 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Issuer symbol
CLYM
Transactions as of
07 Aug 2025
Net transactions value
$0
Form type
4
Filing time
11 Aug 2025, 16:15:08 UTC
Previous filing
01 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas Stephen Basil Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 11 Aug 2025 0002027962

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Award $0 +100,375 +49% $0.000000 304,657 07 Aug 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 27, 2024, the reporting person was granted restricted stock units ("RSUs") to acquire a total of 100,375 shares of common stock that vested based on the achievement of certain performance-based milestones and subject to continuous service. On August 7, 2025, the milestones were deemed to be achieved, resulting in the vesting of the RSUs as to all 100,375 shares.